Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
2003-08-13
2009-12-29
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S234100, C424S248100, C435S041000, C435S243000, C435S440000, C435S471000
Reexamination Certificate
active
07638133
ABSTRACT:
A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.
REFERENCES:
patent: 5504005 (1996-04-01), Bloom et al.
patent: 400973 (1990-12-01), None
patent: 90/00594 (1990-01-01), None
patent: 90/15873 (1990-12-01), None
patent: 92/01783 (1992-02-01), None
Andersson, S.G.E., et al. Codon Usage in theMycobacterium tuberculosiscomplex. Microbiology, vol. 142, pp. 915-925, 1996.
R. Yamaguchi et al., “Cloning and Characterization of the Gene for Immunogenic Protein MPB64 of Mycobacterium bovis BCG”, Infection and Immunity, vol. 57, No. 1, pp. 283-288, 1989.
Andersson et al., “Codon usage in theMycobacterium tuberculosisComplex”, Microbiology, vol. 142, No. 4, pp. 915-925, Apr. 1996.
Edited by the Japanese Biochemical Society, “Shin Seikagaku Jikken Koza, vol. 1, Tanpakushitsu VII -Tanpakushitsu Kogaku-”, Tokyo Kagaku Dojin, pp. 314-315, Feb. 15, 1993.
W. R. Jacobs, Jr. et al., “Introduction of foreign DNA into mycobacteria using a shuttle plasmid”, Nature, vol. 327, No. 6122, pp. 532-535, Jun. 11, 1987.
L. Deml et al., “Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virus Type I Gag Protein”, Journal of Virology, vol. 75, No. 22, pp. 10991-11001, Nov. 2001.
D. L. Narum et al., “Codon Optimization of Gene Fragments EncodingPlasmodium falciparumMerzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice”, Infection and Immunity, vol. 69, No. 12, pp. 7250-7253, Dec. 2001.
M. Uchijima et al., “Optimization of Codon Usage of Plasmid DNA Vaccine is Required for the Effective MHC Class I-Restricted T Cell Responses against an Intracellular Bacterium”, The Journal of Immunology, vol. 161, pp. 5594-5599, 1998.
K. Matsuo et al., “Cloning and Expression of theMycobacterium bovisBCG Gene for Extracellular α Antigen”, Journal of Bacteriology, vol. 170, No. 9, Sep. 1988, pp. 3847-3854.
Honda Mitsuo
Kanekiyo Masaru
Matsuo Kazuhiro
Promkhatkaew Duanthanorm
Department of Medical Sciences Ministry of Public Health of Thai
Swartz Rodney P.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Recombinant BCG vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant BCG vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant BCG vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4146706